Shionogi Launches Cancer Pain Analgesic OxiNorm Powder 0.5% in Japan.Tokyo, Japan, Feb 5, 2007 - (JCN Newswire) - Shionogi & Co., Ltd. has launched OxiNorm powder 0.5% (oxycodone oxycodone /oxy·co·done/ (-ko´don) an opioid analgesic derived from morphine; used in the form of the hydrochloride and terephthalate salts. ox·y·co·done (  k hydrochloride hydrate 1. any compound of a radical with water. 2. any salt or other compound containing water of crystallization. hy·drate (h   dr),
a powder analgesic 1. relieving pain. 2. pertaining to analgesia. 3. an agent that relieves pain without causing loss of consciousness. narcotic analgesic opioid a. nonsteroidal antiinflammatory analgesic (NSAIA) see under drug. for cancer pain, in Japan today. Licensed from
Mundipharma, OxiNorm powder 0.5% is an immediate-release powder
analgesic for treatment of cancer pain with the same active ingredient
as OxyContin Ox·y·con·tin (k s -kn(R) Tablets, also under license from Mundipharma, which
Shionogi launched in July 2003.It is used for adjusting dosage for individual patients to obtain an optimal dose and for swift treatment of sudden pain (breakthrough pain). Combined use of sustained-release and immediate-release analgesics with the same active ingredient and administration route is a method for treating cancer pain recommended in the official journal of the World Health Organization (WHO) and elsewhere. The launch of OxiNorm powder 0.5% will further increase the efficacy of cancer pain management with OxyContin Tablets. Shionogi will dedicate full efforts to appropriately promoting OxiNorm powder 0.5% and OxyContin Tablets, so that all cancer patients can lead peaceful lives free from pain. Product Summary of OxiNorm powder 0.5%
Product name: OxiNorm powder 0.5%
Generic name: Oxycodone hydrochloride hydrate
Manufacturing and
marketing approval: October 20, 2006
NHI drug price listing: December 1, 2006
Launch date: February 5, 2007
Indications: Moderate to severe pain associated
with all types of cancer
NHI drug price: 132.60 yen per gram (at 0.5%)
About Shionogi and Co., Ltd. Shionogi & Co., Ltd, established in 1887 and was incorporated in 1919, is a major research-driven Japanese pharmaceutical manufacturer. The company's primary businesses are research and development, manufacturing, marketing, and import and export sales of pharmaceutical and diagnostics products. Shionogi follows a basic policy of continually providing the superior medicines essential to people's health. For more details, please visit http://www.shionogi.co.jp Source: Shionogi and Co., Ltd. Contact: Public Relations Unit Shionogi & Co., Ltd. Osaka Tel: +81-6-6209-7885 Fax: +81-6-6229-9596 Tokyo Tel: +81-3-3406-8164 Fax: +81-3-3406-8099 Copyright [c] 2007 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion